NEW YORK — Biodesix said Wednesday it has entered a regulatory cooperation agreement with lab equipment firm Streck that will allow it to incorporate Streck's blood collection tubes (BCTs) into its sample collection protocols.
Biodesix said that the agreement will aid its efforts to win US Food and Drug Administration approval for lung cancer companion diagnostics using next-generation sequencing and droplet digital PCR.
"This collaboration with Streck represents a significant step in that process, enabling Biodesix to incorporate Streck’s industry-leading BCTs into our protocols," Scott Hutton, Biodesix's CEO, said in a statement. "The result is a reduced need for specimen processing at the point of collection and easy transport to our lab for testing."
"Partnerships like this one between Streck and Biodesix allow patients to receive critical results that can impact their quality of life and improve health outcomes for those most vulnerable," said Streck CEO Connie Ryan. "We are excited to work with Biodesix as we are both passionate about bringing this cutting-edge technology to the forefront of patient care."
Financial and other terms of the agreement were not disclosed.